GLAXO-WELLCOME RANITIDINE BISMUTH CITRATE PLUS CLARITHROMYCIN NDA STUDIES SHOW 82%-94% ERADICATION OF H. PYLORI; ABBOTT URGES "STRINGENT" TEST STANDARDS
Executive Summary
Eradication rates of ranitidine bismuth citrate plus clarithromycin ranged between 82%-94% in six unpublished studies, Glaxo-Wellcome Gastroenterology Director Arthur Ciociola, PhD, reported at a joint meeting of FDA's Gastrointestinal and Anti-Infective Drugs Advisory Committees Oct. 26.